Complex Civil Litigation Law Firm

If you purchased or acquired securities in Super Micro between April 30, 2024 and March 19, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Super Micro Computer, Inc. (“Super Micro” or the “Company”) (NASDAQ: SMCI) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) a significant portion of the Company’s sales of servers were to companies based in China; (2) these transactions violated U.S. export control laws; (3) there were material weaknesses in the Company’s controls to ensure compliance with applicable export control laws and regulations; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Lead Plaintiff Deadline: May 26, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.

If you purchased or acquired securities in Concorde between April 21, 2025 and July 14, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Concorde International Group, Ltd. (“Concorde” or the “Company”) (NASDAQ: CIGL) and reminds investors of the May 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that Concorde was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (2) that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; (3) that Concorde’s public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Lead Plaintiff Deadline: May 20, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.

If you purchased or acquired securities in Coty between November 5, 2025 and February 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Coty Inc. (“Coty” or the “Company”) (NYSE: COTY) and reminds investors of the May 22, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of Coty’s slowing growth in the beauty market, notably, the Consumer Beauty market was underperforming, margins were compressed by increased marketing investments and there was slowing growth in its Prestige fragrance segme Lead Plaintiff Deadline: May 22, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights. nt. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Coty’s securities at artificially inflated prices.

If you purchased or acquired securities in Atara between May 20, 2024 and January 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) and reminds investors of the May 22, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) certain manufacturing issues, as well as deficiencies inherent in the ALLELE study, made it unlikely that the FDA would approve the tabelecleucel BLA; (2) accordingly, tabelecleucel’s regulatory prospects were overstated; (3) the aforementioned manufacturing issues also subjected Atara to a heightened risk of regulatory scrutiny, as well as jeopardized its ongoing clinical trials; (4) all the foregoing was likely to have a significant negative impact on Atara’s business and financial condition; and (5) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times. Lead Plaintiff Deadline: May 22, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.